Cardiff Oncology Inc (NASDAQ:CRDF) has a beta value of 1.68 and has seen 0.36 million shares traded in the recent trading session. The company, currently valued at $278.64M, closed the recent trade at $4.19 per share which meant it gained $0.61 on the day or 17.00% during that session. The CRDF stock price is -53.22% off its 52-week high price of $6.42 and 52.03% above the 52-week low of $2.01. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.17 million shares traded. The 3-month trading volume is 1.34 million shares.
The consensus among analysts is that Cardiff Oncology Inc (CRDF) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.2.
Cardiff Oncology Inc (NASDAQ:CRDF) trade information
Sporting 17.00% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the CRDF stock price touched $4.19 or saw a fall of -0.96%. Year-to-date, Cardiff Oncology Inc shares have moved -3.49%, while the 5-day performance has seen it change -1.91%. Over the past 30 days, the shares of Cardiff Oncology Inc (NASDAQ:CRDF) have changed -8.55%. Short interest in the company has seen 11.38 million shares shorted with days to cover at 10.81.
Cardiff Oncology Inc (CRDF) estimates and forecasts
The company’s shares have gained 81.32% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -51.20%.
6 analysts offering their estimates for the company have set an average revenue estimate of 87.5k for the current quarter. 6 have an estimated revenue figure of 87.5k for the next ending quarter. Year-ago sales stood 205k and 163k respectively for this quarter and the next, and analysts expect sales will shrink by -57.32% for the current quarter and -51.20% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 19.36% over the past 5 years. Earnings growth for 2025 is a modest 16.14% while over the next 5 years, the company’s earnings are expected to decrease by -7.72%.
CRDF Dividends
Cardiff Oncology Inc is expected to release its next earnings report on 2025-Feb-26 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Cardiff Oncology Inc (NASDAQ:CRDF)’s Major holders
Insiders own 5.62% of the company shares, while shares held by institutions stand at 39.03% with a share float percentage of 41.35%. Investors are also buoyed by the number of investors in a company, with Cardiff Oncology Inc having a total of 142.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 2.63 million shares worth more than $5.84 million. As of 2024-06-30, BLACKROCK INC. held 5.883% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 2.14 million shares as of 2024-06-30. The firm’s total holdings are worth over $4.74 million and represent 4.7816% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of Dec 31, 2024, the former fund manager holds about 1.89% shares in the company for having 1.25 shares of worth $5.35 million while later fund manager owns 1.08 shares of worth $4.61 million as of Dec 31, 2024, which makes it owner of about 1.62% of company’s outstanding stock.
